The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis

Histone deacetylase inhibitors (HDACI) are epigenetic compounds that have been widely considered very promising antitumor agents. Here, we focus on the effects of the pan-HDAC inhibitor ITF2357 (Givinostat) in comparison with SAHA (Vorinostat) in melanoma cells bearing BRAF V600E oncogenic mutation....

Descripción completa

Detalles Bibliográficos
Autores principales: Celesia, Adriana, Notaro, Antonietta, Franzò, Marzia, Lauricella, Marianna, D’Anneo, Antonella, Carlisi, Daniela, Giuliano, Michela, Emanuele, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405675/
https://www.ncbi.nlm.nih.gov/pubmed/36009541
http://dx.doi.org/10.3390/biomedicines10081994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405675/
https://www.ncbi.nlm.nih.gov/pubmed/36009541
http://dx.doi.org/10.3390/biomedicines10081994

Ejemplares similares